Metastatic Pancreatic Cancer
Conditions
Keywords
azeliragon
Brief summary
This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients refractory to prior treatment of metastatic pancreatic cancer.
Interventions
DRUGAzeliragon
Azeliragon is an orally administered inhibitor of Receptor for Advanced Glycation Endproducts (RAGE) which is formulated as a 5mg hard gelatin capsule.
Sponsors
Cantex Pharmaceuticals
Study design
Allocation
NA
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Patient must have histologically confirmed locally advanced or metastatic adenocarcinoma of the pancreas for which potential curative measures, such as resection of an isolated metastasis, are not available. 2. Patient should have previously been treated with a Gemcitabine/Abraxane or FOLFIRINOX- based regimen. 3. Toxicity from prior chemotherapy other than alopecia has recovered to Grade ≤ 1 (CTCAE 1.0) or are at baseline (such as stable G2 neuropathy). 4. Male or non-pregnant and non-lactating female and ≥ 18 to ≤ 80 years of age. 5. Patient has adequate biological parameters as demonstrated by the following blood counts at Screening (obtained ≤ 14 days prior to enrollment) and at Baseline-Day 0: Absolute neutrophil count (ANC) ≥ 1.0 × 109/L; Platelet count ≥ 75,000/mm3 (75 × 109/L); Hemoglobin (Hgb) ≥ 9 g/dL without transfusion or growth factor support 6. Patient has the following blood chemistry levels at Screening (obtained ≤ 14 days prior to enrollment) and at Baseline-Day 0: * AST (SGOT), ALT (SGPT) ≤ 2.5 × upper limit of normal range (ULN), unless liver metastases are present, then ≤ 5 x ULN is acceptable. Total bilirubin ≤ 1.5 × ULN. * Estimated creatinine clearance of \> 60 mL/min (per Cockroft-Gault formula) 7. Patient has ECOG performance status of ≤ 2 8. Patient has been informed about the nature of the study, and has agreed to participate in the study, and signed the Informed Consent Form prior to participation in any study-related activities.
Exclusion criteria
1. Patient has a life expectancy, per investigator assessment, of less than 3 months. 2. Patient has experienced an increase of ECOG to \> 2 between Screening and the time of first dose with study drug. 3. Patient has active, uncontrolled bacterial, or fungal infection(s) requiring systemic therapy. 4. Patients receiving CYP 2C8 inhibitors noted in Section 5.3 of the protocol. 5. Patient has a concomitant serious medical or psychiatric illness that, in the opinion of the investigator, could compromise the patient's safety or the study data integrity. 6. Patient is unwilling or unable to comply with study procedures, including, but not limited to self-administration of oral medication. 7. Patients with a gastrointestinal condition that could interfere with swallowing or absorption. 8. Females of childbearing potential who are sexually active or males with female partners of childbearing potential, where either the female or the male is unwilling to use a highly effective method of contraception during the trial and for 6 months after the last administration of study drug. 9. Patients with concurrent participation in another interventional clinical trial or use of another investigational agent within 14 days of starting study drug. Patients who are participating in non-interventional clinical trials (e.g., quality of life, imaging, observational, follow-up studies, etc.) are eligible, regardless of the timing of participation.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Recommended Phase 2 Dose | 8 weeks | Assessment of the recommended phase 2 dose (RP2D) of azeliragon in patients with metastatic pancreatic cancer. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Pain after treatment initiation | 8 weeks | Pain as determined by Brief Pain Assessment at 2, 4, 6 and 8 weeks after initiation of treatment. |
| Average daily opioid consumption. | 8 weeks | Change in average daily total opioid consumption (in mg of morphine equivalent doses) at Weeks 2, 4, 6, and 8. |
| Plasma CA19-9 levels | 8 weeks | Change in plasma CA19-9 levels. |
| Disease Control | 8 weeks | Disease control as indicated by Complete Response + Partial Response + Stable Disease at 2 months and longer as determined by RECIST criteria, provided CT or MRI scans were performed consistent with standard of care. |
| AE and SAE Frequency | 8 weeks | The frequency of adverse events (AEs) and serious adverse events (SAEs) characterized by type, severity (as defined by the NIH CTCAE, version 5.0), seriousness, duration, and relationship to study treatment. |
| Change in Eastern Cooperative Oncology Group (ECOG) status. | 8 weeks | Measurement of change in grading of patient status based on descriptions in the ECOG performance status scale. Grading scale has a minimum value of 0 and maximum value of 5, with 0 being the best outcome and 5 being the worst. |
| Serum albumin | 8 weeks | Change from baseline in serum albumin concentration. |
| Body Weight | 8 weeks | Change from baseline in body weight. |
| Overall survival | 8 weeks | Measurement of time from first dose of azeliragon until death from any cause. |
Countries
United States
Contacts
Primary ContactStephen Marcus, MD
Outcome results
None listed